Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04144257 (ClinicalTrials.gov)	March 12, 2020	28/10/2019	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Multiple Sclerosis	Drug: [F-18]PBR06;Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital	U.S. Army Medical Research Acquisition Activity	Recruiting	18 Years	60 Years	All	12	Phase 1/Phase 2	United States
2	NCT03207464 (ClinicalTrials.gov)	October 10, 2017	30/6/2017	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Multiple Sclerosis	Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital	NULL	Recruiting	18 Years	60 Years	All	19	Phase 1/Phase 2	United States